These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 19380770)

  • 1. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
    Fourcade J; Kudela P; Sun Z; Shen H; Land SR; Lenzner D; Guillaume P; Luescher IF; Sander C; Ferrone S; Kirkwood JM; Zarour HM
    J Immunol; 2009 May; 182(9):5240-9. PubMed ID: 19380770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
    Fourcade J; Sun Z; Benallaoua M; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Kuchroo V; Zarour HM
    J Exp Med; 2010 Sep; 207(10):2175-86. PubMed ID: 20819923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
    Matsuzaki J; Gnjatic S; Mhawech-Fauceglia P; Beck A; Miller A; Tsuji T; Eppolito C; Qian F; Lele S; Shrikant P; Old LJ; Odunsi K
    Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7875-80. PubMed ID: 20385810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.
    Zelba H; Weide B; Martens A; Derhovanessian E; Bailur JK; Kyzirakos C; Pflugfelder A; Eigentler TK; Di Giacomo AM; Maio M; Aarntzen EH; de Vries J; Sucker A; Schadendorf D; Büttner P; Garbe C; Pawelec G
    Clin Cancer Res; 2014 Aug; 20(16):4390-9. PubMed ID: 24938524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
    Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor antigen-specific CD8
    Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
    Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
    Fourcade J; Sun Z; Pagliano O; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Olive D; Kuchroo V; Zarour HM
    Cancer Res; 2012 Feb; 72(4):887-96. PubMed ID: 22205715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
    Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
    J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutting edge: programmed death-1 up-regulation is involved in the attrition of cytomegalovirus-specific CD8+ T cells in acute self-limited hepatitis B virus infection.
    Zhang JY; Zhang Z; Jin B; Zhang SY; Zhou CB; Fu JL; Wang FS
    J Immunol; 2008 Sep; 181(6):3741-4. PubMed ID: 18768824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.
    Odunsi K; Matsuzaki J; Karbach J; Neumann A; Mhawech-Fauceglia P; Miller A; Beck A; Morrison CD; Ritter G; Godoy H; Lele S; duPont N; Edwards R; Shrikant P; Old LJ; Gnjatic S; Jäger E
    Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5797-802. PubMed ID: 22454499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
    Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
    Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
    Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.
    Rivoltini L; Castelli C; Carrabba M; Mazzaferro V; Pilla L; Huber V; Coppa J; Gallino G; Scheibenbogen C; Squarcina P; Cova A; Camerini R; Lewis JJ; Srivastava PK; Parmiani G
    J Immunol; 2003 Oct; 171(7):3467-74. PubMed ID: 14500642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.
    Fourcade J; Sun Z; Pagliano O; Chauvin JM; Sander C; Janjic B; Tarhini AA; Tawbi HA; Kirkwood JM; Moschos S; Wang H; Guillaume P; Luescher IF; Krieg A; Anderson AC; Kuchroo VK; Zarour HM
    Cancer Res; 2014 Feb; 74(4):1045-55. PubMed ID: 24343228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
    Kudela P; Sun Z; Fourcade J; Janjic B; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2011 Jan; 186(1):312-22. PubMed ID: 21131422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
    Ren Y; Lv Q; Yue W; Liu B; Zou Z
    Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.